Abstract
Observational studies report reduced colorectal cancer in regular aspirin consumers. Randomised controlled trials have shown reduced risk of adenomas but none have employed prevention of colorectal cancer as a primary endpoint. The CAPP2 trial aimed to investigate the antineoplastic effects of aspirin and a resistant starch in carriers of Lynch syndrome, the major form of hereditary colorectal cancer; we now report long-term follow-up of participants randomly assigned to aspirin or placebo.
| Original language | English |
|---|---|
| Journal | Lancet |
| Volume | 378 |
| Issue number | 9809 |
| Pages (from-to) | 2081-7 |
| Number of pages | 7 |
| ISSN | 0140-6736 |
| DOIs | |
| Publication status | Published - 2011 |
Keywords
- Adenoma
- Anti-Inflammatory Agents, Non-Steroidal
- Aspirin
- Chemoprevention
- Colorectal Neoplasms, Hereditary Nonpolyposis
- Dietary Carbohydrates
- Double-Blind Method
- Heterozygote
- Humans
- Starch
Fingerprint
Dive into the research topics of 'Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS